News
Zacks Small Cap Research on MSN49m
MGRM: The De-Risking of the Monogram Story from FDA Clearance and Initiation of Live Patient Trials Supports Price Target of $6.00MGRM READ THE FULL MGRM RESEARCH REPORT Monogram (NASDAQ:MGRM) reported 1st quarter 2025 financial results on May 14, 2025 which were largely in line with our expectations. Research and development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback